About AROG Pharmaceuticals
Arog Pharmaceuticals is a Phase 3 biopharmaceutical company dedicated to developing our lead investigational drug candidate, crenolanib, and a related class of benzimidazole-based compounds to become treatment options for cancer indications with high unmet medical need.
We founded Arog in 2010 after securing exclusive global rights to our product candidates from Pfizer. Since then, we have enrolled hundreds of patients in completed or ongoing clinical trials in acute myelogenous leukemia (AML) and advanced solid tumors.
| Indication | Patient subset | Phase I | Phase II | Phase III |
| FLT3 Pipeline | ||||
| AML | Relapsed/Refractory (2L & 3L) | NCT03250338 | ||
| Newly Diagnosed (1L) | NCT03258931 | |||
| Post-Transplant maintenance | NCT02400255 | |||
| Solid Tumor Pipeline | ||||
| GIST | PDGFRa D842V mutated | NCT02847429 | ||
| Glioma | PDGFRa amplification | NCT02626364 | ||
| Gastric | Relapsed/Refractory | NCT03193918 | ||
Patient Focused Clinical Trial Design
We are currently enrolling multiple global Phase 3 studies designed, if successful, to position crenolanib as a targeted treatment option in combination with intensive chemotherapy for newly diagnosed and relapsed or refractory FLT3 AML and as monotherapy treatment for advanced or metastatic gastrointestinal stromal tumors (GIST) with a D842V mutation.
We are also enrolling clinical studies for advanced second-line gastric cancer in combination with ramucirumab and paclitaxel and as a monotherapy for recurrent or refractory glioblastoma.
Ready to Learn More?
Contact us today and find out how we can help